Clinical neuroscience

— Update from Lancet Commission incorporates vision loss, high LDL to risk factors PHILADELPHIA -- The Lancet Commission on dementia prevention, intervention, and care has expanded the list of modifiable risk factors linked to cognitive decline to 14, after new research conducted since its previous report in 2020. Vision loss and elevated low-density lipoprotein (LDL) cholesterol have been added to the commission's risk factor list, which previously included 12. This revised 57-page

— Potential for durable responses with alternative antigen-targeted therapy A promising new treatment targeting a different antigen has shown success among patients with large B-cell lymphoma who previously relapsed after receiving CD19-directed CAR T-cell therapy (CAR19), according to findings from a phase I dose-finding study. In the study, 38 patients who had not responded to CAR19 achieved a 68% overall response rate and a 53% complete response rate following treatment with autologous